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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Nebivolol is a highly selective beta1-adrenergic blocker that also enhances nitric oxide 
bioavailability via the L-arginine-nitric oxide pathway, leading to vasodilation and decreased 
peripheral vascular resistance. It is marketed in Europe for the treatment of hypertension and 
heart failure and is currently being reviewed for use in the US by the Food and Drug Administra-
tion. Nebivolol appears to be well tolerated with an adverse event proﬁ  le that is at least similar, 
if not better, than that of other beta-adrenergic blockers. Studies suggest that long-term therapy 
with nebivolol improves left ventricular function, exercise capacity, and clinical endpoints of 
death and cardiovascular hospital admissions in patients with stable heart failure. To date, it is 
one of the only beta-adrenergic blockers that have been exclusively studied in elderly patients. 
Additionally, the unique mechanism of action of nebivolol makes it a promising agent for treat-
ment of chronic heart failure in high-risk patient populations, such as African Americans. This 
article will review the pharmacologic and pharmacokinetic properties of nebivolol as well as 
clinical studies assessing its efﬁ  cacy for the treatment of heart failure.
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Introduction
The pathophysiology of chronic heart failure involves a process of left ventricular 
remodeling, whereby molecular changes occur within the myocardium in response to 
mechanical stresses induced by underlying diseases, such as hypertension, ischemic 
heart disease, cardiomyopathies, and valvular abnormalities. Structural changes 
that occur, including left ventricular hypertrophy and/or dilation, typically result in 
decreased left ventricular diastolic or systolic function (Jessup and Brozena 2003; 
Opie et al 2006). This remodeling process is accelerated by the activation of a number 
of endogenous neurohormonal systems including, but not limited to, the sympathetic 
nervous system, which releases high levels of the adrenergic substance norepinephrine 
and stimulates the release of renin in the kidney (Jessup and Brozena 2003; Hunt et al 
2005). The resultant increase in heart rate, contractility, peripheral vasoconstriction, 
and blood volume, as well as the direct toxic effects of norepinephrine on myocytes, 
increases cardiac workload and further impairs cardiac performance (Hunt et al 2005). 
Beta-adrenergic blockers, by suppressing the deleterious effects of norepinephrine have 
become routine therapy for the treatment of chronic heart failure (Hunt et al 2005; 
McMurray et al 2005; Swedberg et al 2005).
The beneﬁ  ts of beta-adrenergic blockers in the treatment of chronic heart failure 
are exclusive to those agents that have demonstrated a survival beneﬁ  t in clinical 
trials and should not, therefore, be considered a class effect. In the US, three beta-
adrenergic blockers are currently available for use in chronic heart failure based on 
evidence demonstrating a survival beneﬁ  t: carvedilol, which blocks alpha1-, beta1-, 
and beta2-receptors; and sustained-release metoprolol succinate and bisoprolol, 
which both selectively block beta1-receptors (Packer et al 1996; CIBIS II Investiga-
tors 1999; Hjalmarson et al 1999; Packer et al 2001; Hunt et al 2005). Nebivolol is a 
third-generation beta-adrenergic blocker that has been marketed and used in Europe Vascular Health and Risk Management 2006:2(4) 465–475
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1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
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for the treatment of hypertension and heart failure (A. Me-
narini Pharmaceuticals 2005; McMurray et al 2005). It is 
currently under FDA review in the US for hypertension and 
it is anticipated that an indication for heart failure will be 
pursued in the near future.
Pharmacology
Nebivolol is a racemic mixture containing equal amounts of 
2 isomers, d-nebivolol and l-nebivolol. D-nebivolol provides 
selective beta1-adrenergic receptor blockade while both 
d- and l-nebivolol cause nitricoxide-induced vasodilation 
(Cockcroft et al 1995; Van Neuten 1998). Nebivolol, which 
has no intrinsic sympathomimetic activity, is considered a 
highly selective beta1-adrenergic blocker due to its 321-fold 
higher afﬁ  nity for human cardiac beta1-receptors versus 
beta2-receptors; it is also more selective for beta1-receptors 
than any other agent in its class (Brixius et al 2001; Bristow 
et al 2005). Unlike other beta-adrenergic blockers with 
vasodilatory properties, nebivolol has no alpha-blocking 
effects (Bowman et al 1994; Van Bortel et al 1997). 
The vasodilatory action of nebivolol is mediated via the 
L-arginine-nitric oxide pathway, whereby nitric oxide pro-
duction by endothelial nitric oxide synthases is enhanced 
(Bowman et al 1994; Cockcroft et al 1995; Ignarro 2004). 
There is evidence to suggest that this mechanism is in part 
due to agonist activity of nebivolol at endothelial beta3-
adrenergic receptors (Figure 1) (Gauthier et al 1998; Gos-
gnach et al 2001; Dessy et al 2005). This was recently tested 
and conﬁ  rmed by Dessy and colleagues who established 
that nebivolol relaxation of human coronary microarteries 
that were precontracted with endothelin-1 was signiﬁ  cantly 
inhibited by bupranolol, a beta1,2,3-receptor blocker, but not 
↑ Endothelial
NOS
L-arginine
Nitric oxide (diffuses into smooth muscle)
Guanylyl
Cyclase
Activated Guanylyl
Cyclase
+
GTP cGMP
Vascular Smooth Muscle
Relaxation
Nebivolol
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Figure 1 The effect of nebivolol on the L-arginine-nitric-oxide pathway. Reprinted with permission Veverka A, Nuzum DS, Jolly JL. 2006. Nebivolol: a third-generation β-ad-
renergic blocker. Ann Pharmacother, 40:1353–60. Copyright © 2006. Harvey Whitney Books.
Abbreviations: NOS, nitric oxide synthase; GTP, guanosine triphosphate; cGMP, cyclic guanosine monophosphate.Vascular Health and Risk Management 2006:2(4) 465–475
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addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
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Nebivolol for chronic heart failure
signiﬁ  cantly inhibited by nadolol, a beta1,2-receptor blocker 
(Dessy et al 2005). Nitric oxide bioavailability may also 
be augmented with nebivolol treatment due to decreased 
inactivation by reactive oxygen entities (Janssen et al 2001; 
Cominacini et al 2003; Pasini et al 2005).
This unique mechanism of nebivolol is particularly 
important due to the critical role of nitric oxide in the 
pathophysiology of cardiovascular diseases, including heart 
failure. In addition to causing vasodilation, nitric oxide also 
inhibits platelet aggregation, atherosclerosis and prolifera-
tion of vascular smooth muscle cells (Mason 2006). When 
endothelial dysfunction occurs, nitric oxide production and 
function is impaired, leading to increased peripheral resis-
tance and a pro-thrombotic and pro-atherogenic environment 
(Panza et al 1990; Moncada and Higgs 1993; Kinlay et al 
2001; Mason 2006). To distinguish the vasodilatory action of 
nebivolol from other beta-adrenergic blockers that selectively 
inhibit beta1-receptors, Lekakis and colleagues tested the 
effect of nebivolol and atenolol on ﬂ  ow-mediated dilation of 
the brachial artery (Lekakis et al 2005). Following 4 weeks of 
drug therapy, patients treated with nebivolol had signiﬁ  cantly 
increased ﬂ  ow-mediated dilation, while those treated with 
atenolol had no change compared to baseline.
The increased bioavailability of nitric oxide with nebivo-
lol treatment may prove to be particularly useful for treating 
African American patients with cardiovascular disease. It 
has been proposed that decreased endothelial nitric oxide 
bioavailability may be more prevalent as an underlying 
cause of cardiovascular disease in this patient subgroup, 
and previous studies of African American patients with 
heart failure have shown a favorable response to therapies 
that increase nitric oxide availability (Taylor et al 2004). 
The mechanism of decreased nitric oxide bioavailability in 
African American patients may be due to oxidative stress 
caused by upregulation of NAD(P)H-dependent oxidases 
and subsequent increases in production of superoxide (O2
–). 
O2
– can react with nitric oxide, decreasing its bioavailabil-
ity and increasing production of the oxidant peroxynitrite 
(ONOO–) (Kalinowski et al 2004). Mason and colleagues 
compared the activity of nebivolol and atenolol on nitric 
oxide release from endothelial cells of age-matched African 
American and Caucasian donors with comparable cardio-
vascular risk histories (Mason et al 2005). Levels of nitric 
oxide, as well as ONOO– and O2
–, the primary components 
of nitroxidative and oxidative stress in the vascular system, 
were measured to assess endothelial function. At baseline, 
release of nitric oxide was 5 times slower, and release of both 
ONOO– and O2
–  was 2–4 times faster in African Americans 
compared to Caucasians. While atenolol had no effect on 
nitric oxide, ONOO–, and O2
– levels in either white or black 
patients, nebivolol treatment increased nitric oxide and 
reduced ONOO– and O2
– levels in African Americans to 
similar levels documented in Caucasian patients.
Pharmacokinetics and drug 
interactions
Table 1 summarizes the general pharmacokinetic properties 
of nebivolol and other beta-adrenergic blockers typically 
used in the management of heart failure (Frishman and 
Alwarshetty 2002; Eon Labs, Inc. 2004; AstraZeneca 
Table 1 Pharmacokinetic characteristics of beta-adrenergic blockers used in the management of heart failure
Characteristic Bisoprolol  (Zebeta®) Carvedilol  (Coreg®) Metoprolol  succinate  Nebivolol
     (Toprol  XL®)
Absorption
 Bioavailability  80%  25%–35%  50%  12%–96%
 First-pass  elimination  Small  Signiﬁ  cant  Moderate  Variablec
  Effect of food  None  Decreases rate but not extent  None  None
   of  absorption
Protein binding  30%  95%–98%  12%  98%
Half-life (hours)  9–12  6–10  3–7   10–30
Hepatic metabolism  50% to inactive metabolites  Extensive primarily by CYP450  Extensive via CYP450 2D6  Extensive via CYP450
  via N-dealkylation and  2D6 and 2C9 to active and  to inactive metabolitesa  2D6 to active and
 O-dealkylation  inactive  metabolitesa,b   inactive  metabolitesa
Renal excretion  50% as unchanged drug,  2% as unchanged drug  95%, 5% as unchanged drug  1% unchanged in urine
  50% as metabolites
Other excretion  2% in feces  Primarily in bile and feces  Minimal
aCYP450 = cytochrome P450.
bCarvedilol is metabolized to a lesser extent by CYP 450 3A4, 2C19, 1A2, and 2E1.
cBioavailability and ﬁ  rst-pass elimination are dependant on cytochrome P450 2D6 genetic polymorphism.Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
465
REVIEW
Leila Fernandes Araujo
Alexandre de Matos Soeiro
Juliano Lara Fernandes
Antônio Eduardo Pesaro
Carlos V Serrano Jr
Heart Institute (InCor), University
of São Paulo, School of Medicine,
Brazil
Correspondence: Carlos V Serrano Jr
Coronary Care Unit, Av. Dr. Enéas
Carvalho Aguiar, 44 – sala 12 – bloco 2,
São Paulo - SP - 05403-900, Brazil
Tel +55 11 3069 5058
Fax +55 11 3088 3809
Email carlos.serrano@incor.usp.br
Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
Coronary artery disease in women: a review
on prevention, pathophysiology, diagnosis, and
treatment
A
u
t
h
o
r
 
c
o
p
y
 
o
n
l
y
Vascular Health and Risk Management 2007:3(5) 650
Veverka and Salinas
LP 2006; GlaxoSmithKline 2007). Nebivolol is rapidly 
absorbed following oral administration, reaching peak plasma 
concentrations within 0.5–4 hours after a dose (Sule and 
Frishman 2006). Food has a minimal impact on absorption 
and therefore nebivolol may be taken without regard to 
meals (Shaw et al 2003a). Nebivolol is extensively metabo-
lized via hydroxylation in the hepatic system to active and 
inactive metabolites. The oral bioavailability of nebivolol is 
dependent on cytochrome P450 2D6 genetic polymorphism 
and so ranges from 12% in extensive metabolizers to 96% 
in poor metabolizers. Similarly, the half-life of nebivolol is 
approximately 10 hours in extensive metabolizers but can 
be prolonged up to 30–50 hours in poor metabolizers (Van 
Peer et al 1991; A. Menarini Pharmaceuticals 2005). Despite 
genetic differences in metabolism of nebivolol, the clinical 
response to the drug appears to be similar (Lefebvre et al 
2006). Nebivolol displays linear kinetics across a dose range 
of 2.5–20 mg, demonstrated by dose-proportional changes in 
maximum concentrations (Cmax) and area under the drug con-
centration curve (AUC) (Shaw 2003b). The average volume 
of distribution of nebivolol is 10 L/kg and this does not appear 
to be affected by patient weight (Cheymol et al 1997). Less 
than 1% of the drug is excreted unchanged in the urine and 
so adjustments of doses in patients with chronic renal failure 
are unnecessary (A. Menarini Pharmaceuticals 2005).
Nebivolol is highly protein bound intravascularly, pre-
dominately to albumin. Studies assessing drug interactions 
with nebivolol in healthy volunteers have found no signiﬁ  -
cant interactions with spironolactone, hydrochlorothiazide, 
digoxin, warfarin, losartan, and ramipril (Lawrence et al 
2003; Morton et al 2003, 2005; Lawrence et al 2005a, b, c). 
Co-administration with cimetidine, a potent inhibitor of cyto-
chrome P450 3A4, increased the bioavailability of nebivolol, 
however this interaction did not inﬂ  uence the extent to which 
nebivolol reduced heart rate and blood pressure (Kamali et al 
1997). Similarly, ﬂ  uoxetine, a cytochrome P450 2D6 inhibi-
tor, resulted in peak plasma concentrations of nebivolol that 
were three times higher than normal (Shaw 2005). Although 
the clinical impact of cytochrome P450 drug interactions 
with nebivolol is unclear, caution should be exercised when 
inhibitors or inducers of 2D6 and 3A4 are used in conjunc-
tion with this agent. At this time, it is also unknown whether 
nebivolol is a substrate of p-glycoprotein and if there is a risk 
of drug interactions at this protein.
Clinical studies
Earlier studies assessing the utility of nebivolol in chronic 
heart failure were limited by small patient populations. These 
studies did suggest, however, that nebivolol would improve 
left ventricular function and mechanics; improve patient 
functional capacity assessed by New York heart association 
(NYHA) classiﬁ  cation; and would at least have a stabilizing 
effect on exercise capacity (Uhlir et al 1997; Brehm et al 
2002). More recently, the ENECA (efﬁ  cacy of nebivolol in 
the treatment of elderly patients with chronic heart failure as 
add-on therapy to ACE inhibitors or angiotensin II receptor 
blockers, diuretics, and/or digitalis) study performed by 
Edes and colleagues evaluated whether nebivolol therapy 
improves left ventricular ejection fraction (LVEF) compared 
with placebo in 260 patients with chronic heart failure (Edes 
et al 2005). The study design also included a secondary 
endpoint to assess the safety and tolerability of nebivolol in 
elderly patients, deﬁ  ned in the study as age greater than 65. 
In addition to the age requirement, patients qualiﬁ  ed for 
enrollment in the study if they met the following criteria: 
NYHA class II, III, or IV; LVEF less than or equal to 35%; 
stable clinical status; and stable therapy for at least 2 weeks 
prior to randomization with angiotensin-converting-enzyme 
inhibitors (ACEIs) and/or angiotensin receptor blockers 
(ARBs), diuretics, and/or digitalis. Patients were random-
ized to therapy with nebivolol 1.25 mg daily, titrated to a 
target dose of 10 mg, or placebo and followed for a period of 
8 months. Intention to treat analysis showed that nebivolol 
therapy signiﬁ  cantly increased LVEF compared with placebo 
(improvement of 6.51 ± 9.15% vs 3.97 ± 9.2% from baseline, 
respectively; p = 0.027), and this was consistent across all 
subgroups examined. Quality of life and changes in NYHA 
functional class were not signiﬁ  cantly improved with nebivo-
lol therapy in this trial. While nebivolol was generally well 
tolerated in this elderly population and did not result in an 
increased number of patients experiencing adverse events 
compared with placebo (81 vs 78, respectively; p = 0899), 
drug-related adverse events were more commonly reported 
with nebivolol vs placebo (40 vs 14; p < 0.0001). The most 
frequent of these were hypotension, bradycardia, and dizzi-
ness. Despite proving in the ENECA study that nebivolol 
is superior to placebo in improving surrogate endpoints of 
chronic heart failure, this study was underpowered to assess 
the effect of nebivolol on clinical endpoints such as overall 
survival, cardiovascular death, or need for cardiovascular 
hospital admission.
Subsequent to the ENECA study, Flather and colleagues 
published the results of the SENIORS (study of the effects 
of nebivolol intervention on outcomes and rehospitaliza-
tion in seniors with heart failure) trial (Flather et al 2005). 
This was the ﬁ  rst and is the only randomized, double-blind, Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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placebo-controlled trial to date assessing the beneﬁ  t of 
nebivolol therapy on morbidity and mortality. The trial 
enrolled 2135 elderly patients, deﬁ  ned as 70 years of age 
or older, with a clinical history of heart failure, deﬁ  ned as 
a documented LVEF less than or equal to 35% within the 
previous 6 months or hospitalization with a discharge diag-
nosis of chronic heart failure within the previous 12 months. 
Patients were enrolled provided they were not currently 
receiving therapy with a beta-adrenergic blocker or had a 
contraindication to treatment. The primary outcome of the 
SENIORS trial was a composite of all-cause mortality or car-
diovascular hospital admission. In the nebivolol arm, doses 
of 1.25 mg daily were initiated and titrated over a 16 week 
period to a target dose of 10 mg once daily. Over a mean 
treatment period of 21 months, 31.1% of patients in the 
nebivolol group reached the primary endpoint compared 
with 35.3% in the placebo group (hazard ration [HR] 0.86, 
95% conﬁ  dence interval [CI] 0.74–0.99, p = 0.039). These 
results imply that 24 patients with chronic heart failure would 
need to be treated with nebivolol for approximately 2 years 
to prevent one death or cardiovascular hospital admission. 
Of note, this beneﬁ  t was observed as early as 6 months 
and was independent of baseline therapy with diuretics, 
ACEIs, digoxin, and/or spironolactone which were used by 
approximately 85%, 82%, 40%, and 38% of patients enrolled, 
respectively. Subgroup analysis determined that nebivolol 
was efﬁ  cacious regardless of age, gender, ejection fraction, 
diabetes, or prior myocardial infarction. At the present time, 
the SENIORS trial is the only assessment of beta-adrenergic 
blocker therapy in an elderly population with chronic heart 
failure. This may be of particular importance in clinical 
practice since the prevalence of heart failure increases with 
age, from 2% to 3% at age 65 years to greater than 80% in 
patients aged 80 years and above (Hunt et al 2005). Addi-
tionally, treatment of elderly patients with beta-adrenergic 
blockers can be more challenging due to desensitization of 
beta-adrenergic receptors and variable pharmacokinetic re-
sponses that occur with age (potentially decreased absorption, 
metabolism and excretion) (Tregaskis and McDevitt 1990; 
Frishman and Alwarshetty 2002). While adverse outcomes 
have been documented when standard therapy for heart 
failure is insufﬁ  cient, it is important to individualize therapy 
for each individual patient (Komajda et al 2005).
There are very few head-to-head comparisons of beta-
adrenergic blockers for the treatment of chronic heart failure. 
Nebivolol has been compared with carvedilol in two small 
trials. Patrianakos and colleagues assessed the effects of 
carvedilol and nebivolol on left ventricular function and 
exercise capacity at 3 and 12 months. Seventy-two patients 
with NYHA class II or III heart failure, speciﬁ  cally non-
ischemic dilated cardiomyopathy documented by a LVEF 
of less than 45% on echocardiogram within the previous 6 
months (Patrianakos et al 2005) were included. Patients were 
randomized to double-blind therapy with either carvedilol 
3.125 mg twice daily or nebivolol 1.25 mg once daily, with 
titration to carvedilol 25 mg twice daily or nebivolol 5 mg 
daily as tolerated. Additional requirements for enrollment 
included stable therapy with an ACEI or ARB for at least 
4 weeks prior to randomization with no new drug therapies 
initiated within 6 weeks prior to randomization. No patients 
enrolled in the study had received prior treatment with a 
beta-adrenergic blocker. At 3 and 12 months, both nebivolol 
and carvedilol caused signiﬁ  cant improvements in LVEF 
compared with baseline. Intergroup comparisons, however, 
revealed that carvedilol provided a greater change in LVEF 
than nebivolol at these time points (3 months: absolute 
improvement of 7.4% vs 4.8%; relative improvement of 
32.1% ± 34.9% vs 15.3% ± 15.9%, mean difference –16.7% 
± 16.5%, 95% CI –29.9 to –3.4, p = 0.004; 12 months: 
absolute improvement of 8.8% vs 6.1%; relative improve-
ment of 35.5% ± 31.9% vs 20.7% ± 19.1%, mean difference 
–14.7% ± 6.4%, 95% CI –27.8 to –1.8, p = 0.02). Both agents 
signiﬁ  cantly decreased left ventricular end-systolic volumes 
at 3 and 12 months and although only carvedilol improved 
left ventricular end-diastolic volumes compared to baseline, 
intergroup analysis showed no statistically signiﬁ  cant differ-
ences in left ventricular volumes across the treatment period. 
Diastolic function, assessed by ventricular relaxation and 
ﬁ  lling patterns, was signiﬁ  cantly improved at 12 months 
with both nebivolol and carvedilol therapy; however, only 
carvedilol demonstrated a beneﬁ  t as early as 3 months.
Exercise duration, measured in seconds, signiﬁ  cantly 
improved at 12 months with both nebivolol (894 ± 381 at 
baseline vs 994 ± 396 at 12 months; p = 0.01, 95% CI –181 
to –18) and carvedilol (982 ± 475 at baseline vs 1124 ± 
427 at 12 months; p = 0.01, 95% CI –248 to –36), with no 
statistically signiﬁ  cant differences observed between the 
two groups. Of note, there was an initial decline in exercise 
capacity detected at 3 months with nebivolol (894 ± 381 at 
baseline vs 795 ± 392 at 3 months; p = 0.07, 95% CI –12 
to –209). Although this was not statistically signiﬁ  cant, this 
effect was not seen in the carvedilol group (982 ± 475 at 
baseline vs 1025 ± 419 at 3 months; p = 0.26, 95% CI –120 
to –33) and compared with nebivolol, exercise capacity at 
3 months was signiﬁ  cantly better with carvedilol therapy 
(p = 0.002, 95% CI 0.03–0.48). One explanation for the Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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initial decline in exercise capacity with nebivolol could be 
too rapid titration of the drug to target doses, which was 
accomplished over 4 weeks, a much faster titration than 
used in the SENIORS trial. Although, this study appears 
more favorable for carvedilol, a subsequent trial published 
by Lombardo and colleagues found conﬂ  icting results (Lom-
bardo et al 2006). A similar patient population, 70 patients 
with NYHA class II or III heart failure and LVEF less than or 
equal to 40%, were randomized to carvedilol and nebivolol at 
similar doses used in the aforementioned trial. Patients were 
evaluated at baseline, 3, and 6 months, but data for baseline 
and 6 months only were reported. In contrast to the study by 
Patrianakos and colleagues, increases in LVEF and decreases 
in left-ventricular end-systolic volumes observed at 6 months 
were not statistically different from baseline; nor was there 
a difference observed between groups. Both carvedilol and 
nebivolol showed a trend towards an increased exercise 
capacity at 6 months and there was no reported decline 
in exercise capacity with nebivolol at earlier assessments. 
Both of these trials enrolled a small number of patients and 
evaluated surrogate endpoints. The study by Patrianakos 
and colleagues was performed in patients with non-ischemic 
dilated cardiomyopathy so extrapolation to the general heart 
failure population is inappropriate given that ischemic heart 
disease is one of the most common causes of chronic heart 
failure. Additionally, target doses of nebivolol 5 mg used in 
these comparator trials is lower than the 10 mg target dose 
used in the ENECA study and SENIORS trial discussed 
above. Any differences between nebivolol and carvedilol 
on clinical endpoints of mortality and hospitalizations for 
heart failure cannot be inferred from these trials. Larger 
trials with head-to-head comparisons of nebivolol, carvedilol, 
metoprolol succinate, and bisoprolol are needed to further 
establish if one agent is any more beneﬁ  cial than the others 
in increasing survival and decreasing hospitalizations for 
acute decompensated heart failure.
Tolerability
Clinical trial data suggest that nebivolol is generally well 
tolerated. Placebo-controlled trials have reported increased 
incidences of drug-related adverse events such as hypoten-
sion, bradycardia, and dizziness but this should be anticipated 
based on the mechanism of drug action (Uhlir et al 1997; 
Brehm et al 2002; Edes et al 2005; Flather et al 2005). 
When compared with other agents in its class, however, 
these adverse events have not been shown to occur any 
more frequently with nebivolol, and in fact there is some 
evidence to suggest that bradycardia occurs less frequently 
with nebivolol than with alternate beta-adrenergic blockers 
in the ﬁ  rst few weeks of treatment (Van Neuten et al 1998; 
Czuriga et al 2003; Grassi et al 2003). The mechanism for 
this has not been well described and, due to the short-term 
duration of the clinical studies, it is unclear if this response 
would be sustained with long-term therapy.
Nebivolol does not appear to impair insulin sensitivity, 
glucose levels or lipoprotein levels and seems to have a more 
favorable effect on these metabolic parameters than other 
beta-adrenergic blockers (Fogari et al 1997; Pesant et al 
1999; Poirier et al 2001; Rizos et al 2003; Celik et al 2006; 
Peter et al 2006). Laboratory assessments of kidney func-
tion, liver function and hematology tests before and during 
therapy with nebivolol indicate no adverse effects on each 
of these systems (Edes et al 2005).
Conclusion
Nebivolol is currently marketed in Europe for the treatment 
of hypertension and heart failure and is under FDA review 
for use in the US. Evidence shows that nebivolol, titrated 
to a maximum dose of 10 mg, is a potentially promising 
therapeutic option for the treatment of chronic heart failure 
when added to standard therapy. Its unique mechanism of 
selectively blocking beta1-receptors and decreasing periph-
eral vascular resistance by enhancing nitric oxide bioavail-
ability distinguish it from other agents in its class; however 
the clinical signiﬁ  cance of this still needs to be deﬁ  ned. Since 
not all beta-adrenergic blockers have proved to be effective 
for the treatment of heart failure, the addition of nebivolol 
to the current armamentarium of carvedilol, metoprolol 
succinate, and bisoprolol is encouraging and provides more 
options for individualizing patient therapy. Speciﬁ  cally, and 
in light of recent evidence for other agents known to work 
via the nitric oxide pathway, nebivolol may prove to be 
more useful than other beta-adrenergic blockers in African 
American patients and those suspected of having decreased 
nitric oxide bioavailability as an underlying pathophysiol-
ogy of disease (Taylor et al 2004). Large-scale clinical trials 
are needed, however, to test this hypothesis. Additionally, 
without head-to-head trials assessing mortality or hospital-
izations for decompensated heart failure with nebivolol, it 
is premature to comment on which beta-adrenergic blocker 
is preferred for heart failure management. Nebivolol is the 
only agent to date that has evidence supporting use of beta-
adrenergic blockers in the treatment of elderly patients with 
chronic heart failure. At this time, numerous clinical studies 
with nebivolol are in progress and include: an assessment 
of the role of nebivolol in the treatment of diastolic heart Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
Coronary artery disease in women: a review
on prevention, pathophysiology, diagnosis, and
treatment
A
u
t
h
o
r
 
c
o
p
y
 
o
n
l
y
Vascular Health and Risk Management 2007:3(5) 653
Nebivolol for chronic heart failure
failure; use of nebivolol in African American patients with 
hypertension; and a comparison of nebivolol and metoprolol 
in patients with subclinical left ventricular dysfunction (The 
Menarini Group 2007).
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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